Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Account Payables
Amounts the company owes suppliers for goods and services received.
Annexon, Inc.NASDAQ: ANNX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 68.0% from a year ago
Account payables stood at $17.53M at the end of Q1 FY2026, up 68.0% from a year earlier and up 17.4% from the prior quarter. Over 3 fiscal years it compounded at +26.3% a year.
Context
- Account payables amounted to 6.7% of total assets at the end of Q1 FY2026, up 3.2 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +68.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 14.93M USD
- Year-over-year change
- +43.2%
- 4-year CAGR
- +7.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.93M | +43.2% |
| FY2024 | 2024-12-31 | 10.43M | +90.0% |
| FY2023 | 2023-12-31 | 5.49M | -26.0% |
| FY2022 | 2022-12-31 | 7.42M | -33.5% |
| FY2021 | 2021-12-31 | 11.15M | — |
Account Payables vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +68.0% is the 2nd highest of 11, against a peer median of -38.3%.
- Account payables amounts to 6.7% of total assets for ANNX, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €18.26M EUR | -49.4% | +34.4% | 4.0% | |
| Mar 2026 | $17.53M USD | +68.0% | +26.3% | 6.7% | |
| Mar 2026 | $14.73M USD | +131.8% | +8.3% | 7.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $12.8M USD | -14.6% | +80.4% | 2.3% |
| Jun 2026 | $12.65M USD | -31.8% | +2.4% | 1.7% | |
| Mar 2026 | $7.52M USD | +22.8% | +11.6% | 2.3% | |
| Sep 2026 | $6.79M USD | -1.9% | +77.3% | 0.9% | |
| Mar 2026 | $4.3M USD | -73.2% | -14.1% | 1.2% | |
| Mar 2026 | CHF 1.32M CHF | -44.8% | +30.6% | 1.0% | |
| Mar 2026 | $653K USD | -75.9% | -15.1% | 1.0% | |
| Mar 2026 | €367.06K EUR | -95.6% | +2.7% | 0.8% | |
| Peer median (excluding ANNX) | — | -38.3% | +10.0% | 1.5% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.84M | 140.02M | 225.11M | 49.5M | 162.05M |
| Short-term Investments | 167.87M | 102.64M | 34.61M | 262.52M | 76.29M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 463K | 203K | 63K | 1.1M | 1.24M |
| Total Current Assets | 247.69M | 248.1M | 263.86M | 316.46M | 242.19M |
| Property, Plant & Equipment (Net) | 38.18M | 35.97M | 32.78M | 29.34M | 25.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 1.03M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.17M | 1.03M | 1.03M | 4.27M | 9.58M |
| Total Non-current Assets | 39.35M | 37M | 33.81M | 33.61M | 35.38M |
| Total Assets | 287.04M | 285.1M | 297.67M | 350.07M | 277.57M |
| Account Payables | 11.15M | 7.42M | 5.49M | 10.43M | 14.93M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.06M | 180K | 5.65M | 5.97M | 8.03M |
| Total Current Liabilities | 21.74M | 22.36M | 17.93M | 30.51M | 42.63M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 33.39M | 31.54M | 29.19M | 26.45M | 23.29M |
| Total Liabilities | 55.13M | 53.9M | 47.12M | 56.97M | 65.92M |
| Common Stock | 39K | 48K | 78K | 109K | 149K |
| Retained Earnings | (296.32M) | (438.26M) | (572.5M) | (710.7M) | (917.39M) |
| Accumulated OCI | (180K) | (372K) | (52K) | 10K | (29K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 231.91M | 231.19M | 250.56M | 293.11M | 211.65M |
| Total Debt | 34.59M | 32.86M | 31.36M | 28.97M | 26.2M |
| Net Debt | (40.25M) | (107.16M) | (193.76M) | (20.53M) | (135.85M) |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.